Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person1
CI&T Inc
Company
Primary record20
Tempus AI, Inc. filed SCHEDULE 13G/A
0001493152-26-049107.txt : 20261028 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001641172-25-010575 0001114238 XXXXXXXX LIVE 2 Class A Common Stock, par value $0.0001 per share 06/18/2025 0001717115 Tempus Al,
CITY OF LONDON INVESTMENT MANAGEMENT CO LTD filed SCHEDULE 13G/A
0001072613-26-000834.txt : 20261023 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001072613-25-000822 0001034546 XXXXXXXX LIVE 4 Common Stock 09/30/2026 0000916618 Morgan Stanley India Investment Fund, Inc. 6174
CITY OF LONDON INVESTMENT MANAGEMENT CO LTD filed SCHEDULE 13G/A
0001072613-26-000833.txt : 20261023 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001072613-23-000106 0001034546 XXXXXXXX LIVE 12 Common Stock 09/30/2026 0000846676 abrdn Emerging Markets ex-China Fund, Inc. 003
IONIS PHARMACEUTICALS INC filed 8-K
Item 7.01 Regulation FD Disclosure. On October 23, 2026, Ionis Pharmaceuticals, Inc. (“ Ionis ”) issued a press release reporting that its partner, Roche, announced late-breaking oral presentation data from the ongoing P
insider_trade
PK!��Q�� [Content_Types].xml �(�̖MO�@����^Q��Bq8�p�R����8Y�_ڝ�� ۉU� �\,�;��~yfr�bM�1i� v��YNz�ݼ`� nF,K(��;(� �� }� *��\Z��ߖ����RKh�+����hͭ��+���o�˄����k{ }H'�qZ�J"jh�pG��`8;��`��� ��pK;�H�y�
Animal and Plant Health Agency awarded £13,808 to GT Vision LTD
Animal and Plant Health Agency awarded a contract to GT Vision LTD worth £13,808 on 2026-10-21. Contract: Supply of Eclipse Ci-L Plus & Accessories. Supply of Eclipse Ci-L Plus & Accessories for APHA Under LUPC framewor
MiniMed Group, Inc. filed 8-K
Item 5.01 Changes in Control of Registrant. On October 15, 2026, the previously announced exchange offer (the “Exchange Offer”) of up to an aggregate of 252,813,348 newly issued shares of common stock of MiniMed Group, I
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-10-13.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-10-08.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-10-02.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-10-01.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-10-01.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-09-29.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-09-29.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-09-23.
CI&T Inc filed 4
SEC form 4 filed by CI&T Inc (CIK 1868995) on 2026-09-15.
Vera Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 15, 2026, Vera Therapeutics, Inc. (the “Company”) announced that TRUTAKNA ™ (atacicept-vymj) met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3
Pyxis Oncology, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 9, 2026, Pyxis Oncology, Inc. (the “Company”) provided a corporate update and issued a press release announcing updated data from its ongoing global Phase 1 monotherapy st
CI&T Inc filed SCHEDULE 13G
0001547676-26-000010.txt : 20260903 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001547676 XXXXXXXX LIVE Common stock 09/02/2026 0001868995 CI&T Inc G21307106 PO BOX 309 UGLAND HOUSE - GRAND CAYMAN E9 KY1-1104 Rule
CI&T Inc filed SCHEDULE 13G
0001547676-26-000009.txt : 20260825 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001547676 XXXXXXXX LIVE Class A common shares 06/18/2026 0001868995 CI&T Inc G21307106 PO BOX 309 UGLAND HOUSE - GRAND CAYMAN E9 KY1-